C.S. Huang

1. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study
   2022/02/16 by L. Gianni, Luca Gianni, C.S. Huang +35 · 2 citations
   Biochemistry, Genetics and Molecular Biology · Medicine · #Breast Cancer Treatment Studies #Cancer Immunotherapy and Biomarkers #HER2/EGFR in Cancer Research